Amy Meister

1.7k total citations · 1 hit paper
9 papers, 674 citations indexed

About

Amy Meister is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amy Meister has authored 9 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Amy Meister's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Amy Meister is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Amy Meister collaborates with scholars based in United States, United Kingdom and Japan. Amy Meister's co-authors include Jonathan D. Cheng, Tanguy Y. Seiwert, Robert I. Haddad, Stephen V. Liu, Ammar Sukari, Joshua Bauml, Steven Powell, Jared Weiss, Lori J. Wirth and Xinxin Shu and has published in prestigious journals such as Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Amy Meister

9 papers receiving 669 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Meister United States	7	551	240	206	136	125	9	674
Xinxin Shu United States	8	582 1.1×	227 0.9×	190 0.9×	196 1.4×	98 0.8×	11	686
Andy Karabajakian France	9	537 1.0×	246 1.0×	163 0.8×	138 1.0×	103 0.8×	19	684
Kristie Lawhorn United States	6	294 0.5×	175 0.7×	117 0.6×	30 0.2×	147 1.2×	11	459
Willa Shi Canada	7	238 0.4×	113 0.5×	237 1.2×	50 0.4×	200 1.6×	7	563
Normando Iznaga Cuba	7	263 0.5×	147 0.6×	70 0.3×	38 0.3×	101 0.8×	14	417
Gustavo Schvartsman Brazil	11	370 0.7×	201 0.8×	24 0.1×	56 0.4×	101 0.8×	31	488
Friederike Göke Germany	11	183 0.3×	100 0.4×	72 0.3×	57 0.4×	280 2.2×	23	514
Yi-Jun Hua China	15	335 0.6×	256 1.1×	575 2.8×	25 0.2×	146 1.2×	18	807
Ming‐Huang Hong China	15	240 0.4×	216 0.9×	391 1.9×	19 0.1×	117 0.9×	17	640
John M. Wallmark United States	8	598 1.1×	278 1.2×	22 0.1×	210 1.5×	99 0.8×	11	748

Countries citing papers authored by Amy Meister

Since Specialization

Citations

This map shows the geographic impact of Amy Meister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Meister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Meister more than expected).

Fields of papers citing papers by Amy Meister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Meister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Meister. The network helps show where Amy Meister may publish in the future.

Co-authorship network of co-authors of Amy Meister

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Meister. A scholar is included among the top collaborators of Amy Meister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Meister. Amy Meister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →

2.

Wagner, Andrew J., Udai Banerji, Amit Mahipal, et al.. (2017). Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 35(12). 1304–1311. 95 indexed citations

3.

Haddad, Robert I., Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Annals of Oncology. 27. vi330–vi330. 11 indexed citations

4.

Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 34(15_suppl). 6011–6011. 14 indexed citations

5.

Mehra, Ranee, Tanguy Y. Seiwert, Amit Mahipal, et al.. (2016). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. Journal of Clinical Oncology. 34(15_suppl). 6012–6012. 31 indexed citations

6.

Wagner, Andrew J., Udai Banerji, Amit Mahipal, et al.. (2015). A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 10564–10564. 8 indexed citations

7.

Powell, Steven, Stephen V. Liu, Ammar Sukari, et al.. (2015). KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.. Journal of Clinical Oncology. 33(15_suppl). TPS3094–TPS3094. 9 indexed citations

8.

Ravandi, Farhad, Ivana Gojo, Mrinal M. Patnaik, et al.. (2015). A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).. Journal of Clinical Oncology. 33(15_suppl). 7070–7070. 5 indexed citations

9.

Le, Dung T., Nilofer S. Azad, Dan Laheru, et al.. (2014). Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.. Journal of Clinical Oncology. 32(15_suppl). TPS3128–TPS3128. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact